Received Sep 2, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MMRV | MEASLES + MUMPS + RUBELLA + VARICELLA (PROQUAD) | MERCK & CO. INC. | 1 | — | — |
| MMRV | MEASLES + MUMPS + RUBELLA + VARICELLA (PROQUAD) | MERCK & CO. INC. | 2 | — | — |
| MMRV | MEASLES + MUMPS + RUBELLA + VARICELLA (PROQUAD) | MERCK & CO. INC. | UNK | — | — |
| MMRV | MEASLES + MUMPS + RUBELLA + VARICELLA (PROQUAD) | MERCK & CO. INC. | UNK | — | — |
No additional AE; inadvertent administration of PROQUAD to a 13-year-old patient.; inadvertent administration of PROQUAD to a 13-year-old patient.; This spontaneous report was received from a medical assistant and refers to a 13-year-old patient of unknown gender. The patient's concurrent conditions, medical history, previous drug reactions, drug allergies and concomitant therapies were not provided. On 22-Aug-2023, the 13-year-old patient was inadvertently vaccinated (Product administered to patient of inappropriate age and Accidental exposure to product) with a first dose of Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live (PROQUAD) (+) STERILE DILUENT (strength, route of administration, site of administration, lot #, and expiration date were not provided); and on 31-JUL-2025, subsequently with a second dose of Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live (PROQUAD) (+) STERILE DILUENT (strength, route of administration, site of administration, lot #, and expiration date were not provided); both given as prophylaxis. No additional adverse event reported. Batch/Lot number is being requested and will be submitted if received.